Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Welcome to the CellaVision DI-60 Q2 Report 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing the Pound Key followed by five on their telephone keypad. Now I will hand the conference over to CEO Simon Østergaard. Please go ahead.
Thank you very much for the intro, and thank you, everyone out there who has an interest in CellaVision DI-60 for tuning in to hear our presentation for the second quarter. In our fiscal year 2025, I have our CFO, Magnus Blixt, with me, and we'll be pleased to present and discuss the report today. Um, the quarter in brief. Basically, we have categorized and labeled our report as presenting robust results with mixed regional performance. And so you can say it's a report where we are reporting 191 million SEK. Uh, top line. Uh, so it represents 2% growth equivalent to 7.8 or almost 8% organic growth given the headwind on the currency of around 6%. It's a report highlighting a quarter where we have had significant contributions from APAC with some truly exceptional contributions. And then we've had quarterly variations from the Americas and EMEA. Given the nature of our business. But I will try to unfold that as we progress. First of all, a few highlights on the progress of our strategic directions while executing the Power of Focus strategy. We actually have made progress on a number of things, with significant advancements on the internal lines. And this quarter, we want to highlight the progress we've made with the bone marrow module. The bone marrow analysis and the clinical trials are very close to completion. And in fact, a number of the studies have been completed. We're continuing certain clinical validations in the US. Um, and here we are reporting pretty much as previously. And here we modify that and say at the beginning of 2026. However, this should still enable our commercial launch in Europe to begin in the beginning of 2026. So things are going according to plan. Uh, a little bit out of our hands with regards to the actual review, um, which includes the work with the notified body, but good progress. And it's been a privilege to follow the program. And now we're really excited to see, and we expect to get the approval. Uh, so that is exciting for us. We're also in this quarter, as you know, those of you who have followed CellaVision DI-60, we have invested significantly in our R&D and development efforts. And here we are highlighting that we're actually coming out with an upgraded software for our CellaVision DI-60, our integrated system with Sysmex. It contains both an improved user interface and several new features, but it also offers seamless integration with the Sysmex, uh, smearing and staining device SP-50. And it is now compatible with our methanol-free stain, which is our proprietary stain. Um, so this is a very important milestone on our journey towards the globalization of our reagent portfolio. Um, so those were the really appropriate highlights to emphasize in this quarter. Let's go to the financial development. Um, so on this somewhat busy slide, uh, but very organized slide, you see our Q2 results spelled out, uh, from a personal perspective, and you have comparison quarters, uh, from last year and year-to-date this year compared with the year-to-date last year. So I said organic growth of almost 8%, and a gross margin, which is higher compared to the comparable quarter last year, it's increased to 68%. Um, so we've had positive contributions, somewhat from price increases, but also negative contributions from FX. Um, we have operating expenses of 41%. As compared to sales, that's primarily due to a slightly higher burn rate in administration, complying with certain systems, regulatory-wise, and slightly increased R&D spending as well, according to our strategy. So that gives us an EBITDA of 60 million, which is comparable to the equivalent quarter, and an EBITDA margin of 31% in line with our corporate objectives. It's 22%. It's increased from 19% to 22%. Um, and in actual numbers, we've spent 42 million versus 36 million last year in the comparable quarter. Um, so here we have approximately 22 million sitting in the P&L, and then we have 20 million capitalized versus last year, where we had 20 million sitting in the P&L and 16 million capitalized. Cash flow-wise, we have an operating cash flow of 58 million this quarter. So we've had a positive contribution from our working capital, namely 7.5 million, primarily due to the fact that we've reduced accounts receivable and decreased our inventory. So that's kind of a shared contribution, if you like, on the investment side. So that leaves us with a total cash flow of -30 million this quarter, which is somewhat stronger than the comparable quarter last year. Still a very healthy company from a financial perspective with hardly any debt. And, um, we have cash and bank equivalents of 155 million sitting on the balance sheet as of today, as of this quarter. Let's try and unfold the regional highlights on the top line, looking at what happens in the Americas. And, um. And APAC. As for the Americas, um. We had an organic growth of 5%. And so that was equivalent to 66 million. So, we had pretty healthy contributions from our integrated systems. The DI-60. However, we had a softer contribution this quarter from our DC one instrument sales, catering to the smaller laboratories. Um, say our analysis is probably more related to internal matters on the diff line where we've been transitioning from one smearing device, where we've had issues, to a more simple smearing device. So, that has impacted the demand side. We still see continued progress in expanding our market presence in Latin America and especially in countries like Brazil, where we see attraction for the DC one instrument format. So, we were reporting 80 million here. Um, it's a little bit mixed, large and small. But what is good to hear is that there is actually momentum across multiple countries. Uh, also when we have communication with our key partner, there are orders coming in from multiple countries. Um, but of course, there's a slight softness in order placement for installation. That is the nature of the process, balancing the time between receiving orders from the lab and the installation phase. Um, and then, uh, I can talk to APAC where I would say a very strong APAC 46 million organic growth equivalent to 27%. Um, um, after the 5% currency effect there, um, there is a contribution, uh, sort of in general from APAC, but also an exceptional contribution. Since strategically, we've been running a program where we are manufacturing the DI-60 out of China. Um, and as part of that, um, process, we have shipped a number of, um, components, uh, going to the Made in China manufacturing line, which is what you also see in our numbers with an exceptionally high, um, contribution from APAC and especially to China. Um, but again the broad integrated solution is strong. And we have also, over the years, you can say, centralized and streamlined our commercial operations across APAC to really work closely with our key partner, Sysmex. But we have actually also expanded in Southeast Asia with the resources to help us and Sysmex drive growth in the region. So we're still investing in sales and marketing. Also on the research side. Yeah, this chart shows sales per product group, which is when we categorize the revenue into product categories: instruments, reagents, software, and others where others refer to our spare parts and oil consumables. Um, um, and here I think I already talked about the instrument dynamics. Uh, but in general this quarter, it is the large instruments that remain the significant driver. We do have some product mix within that category as well. Uh, but also across the small, um, instrument category, as I alluded to. Um, what I want to highlight on the reagents is especially for the EMEA, where we have 20% growth compared to the comparable quarter for hematology reagents. So, hematology reagents, and especially in EMEA where we have the majority of our sales, are really growing healthily, up double digits, which is in line with our strategy. And good to see again our reagent expansion, a strategic pillar, embraces both APAC and the US. However, it's still small numbers spread across multiple markets, but we are increasing with, um, from 1.5 to 1.8 and about a million in increase compared with 2.3 million last year, year to date and 3.2 now. So it's about a million we've grown year to date compared with the comparable quarter. So, that's of course smaller numbers. But the big driver in APAC is China, where we are working on our distribution setup to eventually get into China and combine that with our total offering. As the only solution provider who can deliver both instruments, reagents, and superior software. Um, and for the US, I should also mention that the MCDh is now available with our software upgrade. I think that is extremely strategically important; that milestone endorses our opportunity to bring MCDh both to Europe, and of course, also to the US, where we have a large opportunity to improve and deliver a much, much more environmentally friendly solution to the labs. So that is a key milestone that you will hear more about as we plan the big launch for autumn. Um, yeah. And the remaining part around software is pretty much in line with our installed base and our instrument sales. So let's take the key takeaways. It's a bit extensive. Um, but I'm actually pretty proud of what we are reporting on this slide again. Uh, we see, um, this mixed regional performance. Um, but we see organic growth. Uh, there is some, uh, let's call it not seasonality, but there is a function as to when we hear about orders at hospitals versus when we need to deliver. Um, and if I look at the power of our focus strategy, and I think about the strategic partnership that we have closed, we're continuing to renew and improve the way we work, especially in our marketing efforts. Uh, sales-wise, sales support-wise, but we're also increasing our engagement in the investment program and really making some progress. And I think these bullets speak to our progress. Uh, the clinical trials for bone marrow are now completed for Europe. Uh, and we can really start to envision our CE Mark. There is obviously uncertainty around when you file before you get the actual approval of your documentation. However, we are confident that we will have the CE mark by the beginning of 2026, leading to our launch. I have introduced today, without explicitly announcing the actual launch and the content, but we're very proud and I'm very proud of the team who has achieved this improved software version that we will launch this year. Um, and then I also want to emphasize that our R&D spending entails the adaptation of our superior Fourier Ptychographic Microscopy technology, which we are integrating into our core hematology business and developing as the next generation solution. So that is progressing according to plan. Um, and the continued exploration of our FPM in adjacent fields such as pathology and cytology is also progressing, where we are continuously refining and improving the technology and engaging in external conversations about this superior and proprietary technology. So we do continue on our journey to push the limit of delivering cutting-edge solutions, reaffirming our market position in line with our strategic plan. So finally, I mean, before we go to the question and answers, I think it's a super special day for me, and not the least for Magnus. Uh, our CFO, um, Magnus has decided to leave CellaVision DI-60 after 12 years. Uh, so this is actually your final call. That's right. You've been there, almost sitting here 50 times, I guess. Um, um, but of course, I want to thank you so much for what you've done for the company, the journey you've been on from a very small to a mid-sized company, where we are on a very interesting trajectory. Uh, I think with your capabilities, you will have all opportunities, uh, going forward, but I, of course, want to thank you also in this community where you work closely with multiple investors, for everything you have done for the company. Um, so thanks, Magnus.
Thank you. Simon. It's been excellent. 12 years. Thanks a lot.
Wonderful. And with that, I think it's appropriate to open the mic and have some questions for those who have not reached the beach yet. Thank you very much for listening in.
He wished to ask a question. Please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.
Thank you very much and I hope you can hear me. All right. Um, a few short questions on my end. Uh, first, being related to the deliveries to China, did we consider this to be a sort of inventory build-up and for this to potentially be sequentially a little bit weaker in the coming quarters? That would be my first question.
Um. Thanks, Rick. Um, I would say that what you imply in the question is likely the case. That's probably a fair assumption. So, we've shipped multiple components and modules to China, which is part of validating the manufacturing line. And they will be targeted for the Chinese market. So, we could expect a little bit of weakness coming from that situation. However, we still see demand from the Chinese market. Um, so, but the assumption is fair. Uh, I think with your capabilities, you will have all opportunities, uh, going further, but I, of course, want to thank you also in this community where you work closely with multiple investors to thank you for all you have done for the company.
Great. Thank you. And kind of a follow-up on that, in my mind, this mix of CellaVision DI-60 in combination and integration with the smearing device and the methanol-free reagents is a bit ahead of its time. Um, and it's a big opportunity for you to grow globally with your reagents. So kind of, sort of, multiple questions here. How should we view this in the short term in terms of the global ramp-up of this? Um, how unique is this product? And thirdly, how does it compare in terms of pricing to your legacy products regarding reagents?
Yeah, I think what we're reporting here is, um, also if we go years back, at the capital market day, we said there's a prerequisite that needs to be fixed in order for us to actually run MCDh, especially with Sysmex on the SP 50. And that is what we are reporting; that seems to be fixed by now. That's really a milestone. So where we are is that we can now start to gather customer feedback from the stains. And so, it doesn't just jump straight into a launch plan, but the launch is not too far away. It is a function of, and it's a decision also made by Sysmex, obviously, as to when and where. But, the launch for next year is primarily what you should be looking at. But it's a major milestone and it's a major opportunity now to finally start considering and opening up the market opportunity in the US where we hardly have any sales today. With regards to the.
And just in terms of, yeah.
Yeah. With regards to the pricing piece, that is a balance, and I think I'm not going to comment on that. That's obviously also a question or a discussion we have with Sysmex. It's also a function of the final protocol in terms of the consumption of the different reagents where the specific cost lands. Uh, but there might be a slight adjustment to the pricing. Of course, it comes with a higher value proposition than the classic stains, as it's environmentally friendly. There's also improved waste management, and there is less service needed when you start running the real stains, including the methanol-free. So there is an operational improvement, which should also be reflected in the pricing.
Great. And the last question on my end relates to these prolonged order-to-installation times, which we have seen across the board for many companies. So just how much of a delay or postponement are you experiencing based on historical numbers?
Yeah. Yeah. Typically, we've used to say that from orders placed by labs. Even though it can take many years, we've typically said 2 to 6 months. Uh, but now we're seeing that it's probably more five to nine months. Um, so there is a little bit more slack in when the orders come in. And then, when is everything aligned to actually do the implementation? When our resources at the laboratories, IT, etc., are available for the actual implementation. available for the actual implementation. So, that's a little bit prolonged, but it's not significant; however, it is prolonged.
Great. Thank you very much. And now, unfortunately, I didn't have any questions for you, Magnus. But thanks for all the support throughout the years and good luck in your future endeavors.
Thank you. Appreciate it.
Yeah, thanks. Alright.
The next question comes from Richard Romanus from Redeye. Please go ahead.
Um, hello. I had some questions. Um, could you tell us the sales potential for the bone marrow, um, application?
Yeah. So the bone marrow application is what we define as, um, it's under the header of our specialty analysis. So, it's an analysis that is done. Uh, actually, this is not done on the peripheral blood, but it's done on the bone marrow samples. So it's more of a specialty analysis. And we believe that the market potential is close to 1 billion SEK per year. Um, and the majority of that figure pertains to the entire specialty segment. But the majority of that, which is actually the biggest application or opportunity, refers to bone marrow. And so, I would say that the majority of that number is bone marrow. It's a market that sits in the large lab segment. So it's a market where we anticipate we can target it, or we will target it, with our DC one platform. So the instrument that was previously positioned for the small lab segment will now be the engine targeted for the large lab segment, and it will host the actual software application. The API that classifies the different cells in bone marrow. So it's an opportunity that sits in the large lab segment for the majority. That's how we read the market and where we expect to generate the revenue from.
Would you say this is an opportunity to upsell the DC one instrument?
Yes. So yes, it will expand the addressable market for DC One. I think I'll phrase it that way because the DC One was originally designed for the small labs segment. Um, but given the fact that very few labs have a high number of bone marrow samples, it can actually easily accommodate the needs of bone marrow analysis in the large lab environment. Um, so it's really about tying into the large lab and being an opportunity for the large lab to standardize their workflow and save time when they conduct bone marrow analysis, assisting their bone marrow analysis, which is a critical analysis because it typically involves dealing with leukemia and lymphoma patients. So it's advancing into supporting severe patient diagnosis.
Very well. Um, I had a modeling question, but, um, I could rephrase it. Uh, like this. You're investing substantial amounts of money, whether through costs, R&D, or capitalization. Um, but once these investments are completed, how do you think that will affect your EBITDA margin? And, um, do you think it will improve, or do you think you will always have a similar level of investment into research and that the investments will simply translate into better sales?
Yeah, that's a tricky one in terms of outlook.
I would say, though, that the value creation we, as an innovation company, can achieve is strongly tied to investing in our own programs. So I think the shareholders are very well off with our approach to continuously develop and innovate. I think that is what we are proving with the power of focus strategy, where we have increased our spends over the years. Um, but now we're actually starting to see things come out of it. So I think it's important for us to stay faithful to the innovation profile and that translates into investments. However, I would also emphasize that we are in a phase where we have invested in multiple strategic pillars, which has significantly increased our investment profile. Uh, there is a scenario where we can lower it slightly. However, we are looking to invest in new projects outlined in our roadmaps after having completed what is already planned there. So I don't want to send the expectation that we just get through and then we harvest based on whatever innovation we have. Having said that, I'm cautiously saying that we know we're at a high level and could potentially bring it down, but I really want to reserve and be transparent to the shareholder community that we are an innovation company. I think that's why our raison d'etre, if you will, is about driving innovation. This is why we've been successful. So we shouldn't abandon that profile. Uh, but there can be a little bit of, let's call it a financial upside. Uh, given the fact that we're in a historical situation right now, that was a little bit wordy, but I hope it clarifies our stance. I hope you understand my perspective here.
Yeah. Yeah, it certainly makes sense. Perhaps a bit. A bit of both. I interpreted it as a slight modern improvement, but also a heightened sales trajectory would be my understanding. But, um, could you say also how much or rather, um, can you capitalize any of the investments going into the project?
Yeah. So I think it's, um, it's twofold. So we capitalize investments that go into FPM on the hematology analyzer that we've, as we also show here on the actual slides, where we're talking about the adaptation of FPM for our core hematology business that is capitalized because that is due to the maturity level of the program. Um, however, if we have activities on FPM where it's more immature or you can say it's in the innovation phase, such as feasibility testing, that is not capitalized. Uh, that is sitting in the P&L right away. So we have a development model where, after a certain stage gate, we start capitalizing. But certain prerequisites need to be in place in order for us to capitalize. So that is really how you should do it. So it's a little bit of a mixed bag, but the majority of the program is on the hematology side and that is capitalized. I know you will correct me if I'm off track.
I'm nodding here. You can't hear it, but I'm nodding. And I agree with what you say. Having said that, I'm cautiously saying that, hey, we know we're at a high level and we could potentially bring it down, but I really want to reserve and be transparent to the shareholder community that we are an innovation company.
Having said that, I'm cautiously saying that, hey, we know we're at a high level and we could potentially bring it down, but I really want to, um, reserve and be transparent to the shareholder community that we are an innovation company. Last question. You have a quite healthy balance sheet. Cash is under 55 million with very limited loans. Um, uh, why do you maintain this position instead of, let's say, paying it out in dividends? Are there any potential uses, like acquisitions?
It's a great question. And it's obviously also an ongoing discussion, I should say, that we have in the boardroom as to how to leverage our financial situation. As you can hear, we are very cognizant that the key value driver is actually investing in our own programs. And in terms of acquisitions, uh, we acquired the FPM technology. We acquired the rail diagnostics, which we believe are truly long-term attractive and successful acquisitions. And so we are not rejecting that. Or if there is technology that comes along or other opportunities. Also, supply chain-wise, there can be opportunities to expand our business. Um, we may pick up something along those lines, but it is also important for me to emphasize that the vision we have with the Power of Focus strategy is building the digital ecosystem. So everything has to work within our current solutions, which makes it a little bit more difficult just to plug and play something from the outside. Um, and this is also part of the secret to why CellaVision DI-60 has been successful in building something that really works. We also observe that new entrants in this field find it challenging to make things work efficiently, which is why M&A targets Uh, there are not that many that fit into our core hematology strategy, but outside and supply chain-wise, there could be opportunities. And this is where we're well suited to onboard such an acquisition if we see someone is a fit.
Cash, um, under 55 million, um, with very limited loans. Cash, under 55 million, very limited loans. Thanks for answering my questions.
Thanks, Richard.
Next question comes from Ludvig Lundgren from Nordia. Please go ahead.
Cash, um, under 55 million, um, very limited loans. Hi, Simon and Magnus. Um, first, I wanted to continue a bit on Richard's question regarding R&D costs. So R&D was 43 million here in Q2, and is it possible to quantify how much of this relates to the bone marrow application? And maybe if you have any external costs here at the end of this project that might disappear when you launch this product.
Mhm. Yeah. I think I can start answering a little bit. Overall, the actual cost for the bone marrow has increased given the fact that we are using external labs for the clinical validations. So the burn rate for the bone marrow program in these last two quarters has been somewhat higher, I would say. Um, I'm not sure we dissect our cost base on a project basis, so I'd probably be a little bit cautious in doing so. Um, but, um, it has been significant, and I should also emphasize that all the costs related to the bone marrow analysis that we're using have been capitalized. Um, but it's a significant program. And it's, um, it's not just a small thing, uh, which is also why it has taken us three years to, to bring it out.
Okay, great. So, yeah, I assume then that a significant part of the increase here on the capital side then relates to these external programs. Um.
Yes, it's external. Um, it's a ramp-up on the bone marrow, but it also entails a ramp-up on our other investment programs. And you can see them here. Um, we are also emphasizing the fact that we've made a big milestone with our software upgrade that will be launched in autumn, and we are pursuing our next generation. So they are also, um, maybe I'd say incrementally improving. You're right. The majority could be, uh, bone marrow. That's a fair assumption, actually. That's a fair assumption, actually. But. But the others have also increased. Um, at least according to my, um, the details.
I think I can start answering a little bit. I think I can start answering a little bit. I think I can start by answering a little bit. Um, and then I wondered a bit about funnel activity here during the quarter. Um, and if you've seen any change in customer behavior throughout the quarter or if that's been stable throughout these months.
The situation has remained relatively stable, despite a quarter that has been politically very unstable. Then we haven't actually received feedback indicating that it has led to significant instability in terms of order placement. Um, along the lines of what we saw in Q3, Q4 when we had the presidential elections. We've heard nothing about that, basically.
Okay. Thank you. And then the final one, wondering about this software upgrade for the disks that you mentioned. What will the sales process look like for this? Um, and is there a significant price difference compared to the software that you currently have for this product?
Now the sales models. So this is our integrated product with Sysmex. So that will continue according to plan. However, uh, the user experience and also several new features, um, including, uh, you can say a tighter integration with Sysmex, uh, will, um, make us, uh, more competitive also in accounts where, uh, they are about to replace. Then, this will be a very attractive, um, product upgrade, uh, in order to replace and choose, uh, another DI-60. So you could see it as a lifecycle management move with significant customer value. That's how you should look at it.
Okay, so it's mainly two new DI installations then, I suppose.
And two new accounts. It will be even more attractive to choose it. So, but what I'm saying is that, of course, it will significantly improve for accounts that have been running or are changing the bloodline here, as they will actually get more customer benefits.
Okay, great. Those were my questions. Um, so, yeah. Good luck to you, Magnus. And thanks for the help. Uh, all the help during these years.
Thank you. Ludwig.
Yeah. Thanks, Ludwig.
The next question comes from Bobby Power from Liontrust Asset Management. Please go ahead.
Uh.
Hi there. Hopefully, you can hear me.
Yeah. Very well. Thanks.
Yes. Brilliant. Thank you very much for the presentation, Simon. And congratulations on a great 12 years. Magnus. Um, I just had a question regarding your comment about the small labs, where you've noticed a slight reduction in demand in the US. I just wondered if you could provide a bit more detail on the drivers behind that and whether it's been a phenomenon observed only in the Americas this quarter or in other regions as well? Thank you.
Yes, certainly. No, we've been, um, a little bit exposed due to issues with one of the components in what we call the diff line, specifically the smearing component, where we've encountered some inconsistencies. Um, so we are doing a root cause analysis on this smearing device. Um, that is what has hindered and impacted our DC-1 sales. That's how we analyze the situation. So you should see my comment as more of an internal issue affecting the customers, rather than a change in demand for the DC-1. Um, so this is an internal matter that we are searching for the root cause. Uh, also with the mitigation strategy, you have a simpler smearing device, which we already have, that will be positioned together with the stain box and the DC one. So that's kind of how we should look at it. And that has, I should add, impacted us the most since historically we've seen the small lab market as being very attractive for the DC-1 and it still is, given the network structures of hospitals, which we also see in Europe, but not to the same extent. So, so this is why our numbers in the US have been more affected than in Europe.
Brilliant. Thank you very much. Um, and then I just had a second question regarding, um, I think you mentioned pricing has been a positive contributor in the quarter. I just wondered if you could talk through your pricing strategy for this year compared to last year. Great. Thank you.
Yes. So essentially, the pricing, for the majority of our offerings, involves annual price adjustments. Um, the reason why you can say we don't have the full impact of the price adjustments in Q2 is that everything booked for delivery in Q2, but placed prior to Q2, is charged based on the previous pricing scheme. This is why the full impact of the price adjustments typically takes place as per. 1st of April comes into effect in Q3. That's kind of the dynamic. Um, and that is for the majority of our business, we do have multiple contracts. Also on the reagent side and so forth. Um, but I'd say in general for the instrument side. Given the fact that we are selling, most of our business goes via Sysmex. And that is the main contributor.
And the timing of the price increases. It's the same. This year, it's the same as it was last year.
Yeah. That's right.
Thank you so much, guys.
Pleasure. Thanks for the questions.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Yeah, thank you very much. And thank you, everybody out there listening in. We appreciate your interest in CellaVision. As you know, my closing comment is really that today we are reporting robust results with regional performance. And I think what I reflected upon is that three years after communicating the vision of CellaVision DI-60, which we captured in the Power of Focus strategy, I'm extremely proud on behalf of the team to say that our output is really starting to get out there. We are starting to unfold the many investment programs we have internally. So even though there are always uncertainties and challenges when dealing with regulatory approvals and so on, we are confident across our strategic pillars that we will make a difference and launch truly superior contributions to our winning ecosystem. Um, so thanks again for the continued attention. As I said, uh, also thanks to all our staff for making this happen. Uh, you all deserve a very, uh, very good summer break. And I'm sure the ones on the call also deserve a summer break. So, um, finally, thanks to you, Magnus, you certainly also deserve a summer break. Um, we will be back here in autumn. Uh, I think we have our next call on November 6th, where we report on the Q3 results. Um, we will do a lot of hard work, uh, before then, but for now, I wish everybody a great summer and, uh, take care out there. Thanks.



















